ArcticZymes Technologies (AZT) Hisse Özeti
Bir yaşam bilimleri şirketi olan ArcticZymes Technologies ASA, Norveç, Almanya, Litvanya, Fransa, İtalya, Birleşik Krallık, Avrupa'nın geri kalanı, Amerika Birleşik Devletleri ve uluslararası alanda moleküler araştırma, in vitro teşhis ve biyo-üretimde kullanılmak üzere rekombinant enzimler geliştirmekte, üretmekte ve ticarileştirmektedir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 3/6 |
| Gelecekteki Büyüme | 4/6 |
| Geçmiş Performans | 4/6 |
| Finansal Sağlık | 6/6 |
| Temettüler | 0/6 |
AZT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
ArcticZymes Technologies ASA Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | NOK 20.60 |
| 52 Haftanın En Yüksek Seviyesi | NOK 31.40 |
| 52 Haftanın En Düşük Seviyesi | NOK 15.00 |
| Beta | 0.54 |
| 1 Aylık Değişim | 2.49% |
| 3 Aylık Değişim | 2.49% |
| 1 Yıllık Değişim | 22.99% |
| 3 Yıllık Değişim | -45.93% |
| 5 Yıllık Değişim | -76.84% |
| Halka arzdan bu yana değişim | -17.60% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Apr 27
AZT: Enzyme Platform Expansion And Investor Day Will Support Future Upside
Analysts have slightly reduced their price target on ArcticZymes Technologies from NOK 32.50 to NOK 32.00, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E. What's in the News ArcticZymes Technologies is holding an Analyst and Investor Day focused on how the company has completed its commercial transformation (Key Developments).Anlatı Güncellemesi • Apr 12
AZT: Enzyme Platform Scaling And Analyst Day Will Support Future Upside
Analysts now keep their price target for ArcticZymes Technologies steady at NOK 32.50, reflecting largely unchanged assumptions for fair value, discount rate, revenue growth, profit margin and future P/E in their models. What's in the News ArcticZymes Technologies plans an Analyst/Investor Day to outline how the company has completed its commercial transformation and is now focused on scaling its enzyme platform across biomanufacturing and molecular tool markets (Key Developments).Recent updates
Anlatı Güncellemesi • Apr 27
AZT: Enzyme Platform Expansion And Investor Day Will Support Future Upside
Analysts have slightly reduced their price target on ArcticZymes Technologies from NOK 32.50 to NOK 32.00, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E. What's in the News ArcticZymes Technologies is holding an Analyst and Investor Day focused on how the company has completed its commercial transformation (Key Developments).Anlatı Güncellemesi • Apr 12
AZT: Enzyme Platform Scaling And Analyst Day Will Support Future Upside
Analysts now keep their price target for ArcticZymes Technologies steady at NOK 32.50, reflecting largely unchanged assumptions for fair value, discount rate, revenue growth, profit margin and future P/E in their models. What's in the News ArcticZymes Technologies plans an Analyst/Investor Day to outline how the company has completed its commercial transformation and is now focused on scaling its enzyme platform across biomanufacturing and molecular tool markets (Key Developments).Anlatı Güncellemesi • Mar 29
AZT: Enzyme Platform Scaling Across Biomanufacturing And Molecular Tools Will Drive Future Upside
Analysts have maintained their price target for ArcticZymes Technologies at NOK 32.5, noting only minor adjustments to factors such as the discount rate, revenue growth assumptions and future P/E that do not materially affect their overall assessment of fair value. What's in the News ArcticZymes Technologies is holding an Analyst and Investor Day focused on how the company has completed its commercial transformation.Anlatı Güncellemesi • Mar 14
AZT: Enzyme Platform Scaling Across Biomanufacturing Markets Will Support Future Upside
Analysts have slightly adjusted their price target for ArcticZymes Technologies to NOK 32.50, reflecting modest tweaks to their discount rate, revenue growth expectations, profit margin assumptions, and future P/E inputs, while keeping their overall fair value view unchanged. What's in the News ArcticZymes Technologies is holding an Analyst and Investor Day to explain how it has completed its commercial transformation.Anlatı Güncellemesi • Feb 27
AZT: Enzyme Platform Scaling Across Biomanufacturing Will Drive Future Upside
Analysts have trimmed their price target for ArcticZymes Technologies to NOK 32.5 from NOK 40.20. They cite slightly lower assumptions for long term revenue growth, profit margin and future P/E, along with a modestly higher discount rate in their models.Analiz Makalesi • Feb 15
Results: ArcticZymes Technologies ASA Beat Earnings Expectations And Analysts Now Have New Forecasts
As you might know, ArcticZymes Technologies ASA ( OB:AZT ) just kicked off its latest full-year results with some very...Anlatı Güncellemesi • Feb 13
AZT: Buyback Program And Platform Scaling Will Support Future Upside
Analysts have nudged their price target for ArcticZymes Technologies to NOK32.50 from NOK32.00, reflecting updated views on slightly adjusted revenue growth, profit margin assumptions and a higher future P/E multiple. What's in the News ArcticZymes Technologies plans an Analyst and Investor Day to explain how it has completed its commercial transformation and is now focused on scaling its enzyme platform across high growth biomanufacturing and molecular tool markets (Key Developments).Anlatı Güncellemesi • Jan 23
AZT: European Distribution Deal And Buyback Will Support Future Upside
Analysts have kept their fair value estimate for ArcticZymes Technologies steady at NOK 32.0 per share, indicating only minor adjustments in assumptions such as the discount rate and future P/E, rather than any major change in their overall view. What's in the News ArcticZymes Technologies ASA plans to start share repurchases on November 25, 2025, under an AGM mandate from May 27, 2025.Analiz Makalesi • Jan 08
Subdued Growth No Barrier To ArcticZymes Technologies ASA (OB:AZT) With Shares Advancing 25%
Those holding ArcticZymes Technologies ASA ( OB:AZT ) shares would be relieved that the share price has rebounded 25...Anlatı Güncellemesi • Jan 07
AZT: European Distribution Agreement And Share Buyback Will Support Future Upside
Analysts have maintained their fair value estimate for ArcticZymes Technologies at $32.0. They cite unchanged assumptions on discount rate, revenue growth, profit margin and future P/E as the basis for leaving their price target intact. What's in the News ArcticZymes Technologies ASA started a share repurchase program on November 25, 2025, under an authorization from the May 27, 2025 Annual General Meeting.Analiz Makalesi • Jan 07
Are Investors Undervaluing ArcticZymes Technologies ASA (OB:AZT) By 50%?
Key Insights The projected fair value for ArcticZymes Technologies is kr45.44 based on 2 Stage Free Cash Flow to Equity...Anlatı Güncellemesi • Dec 23
AZT: European Distribution Deal And Buyback Program Will Drive Future Upside
Analysts have modestly raised their price target on ArcticZymes Technologies to NOK 32.00, reflecting slightly lower perceived risk and continued confidence in the company’s robust growth and margin profile. What's in the News ArcticZymes Technologies has commenced a share repurchase program starting November 25, 2025, allowing buybacks of up to 2,500,000 shares, or 4.90 percent of outstanding share capital.Anlatı Güncellemesi • Dec 09
AZT: European Distribution Deal Will Drive Future Demand And Margin Strength
Narrative Update on ArcticZymes Technologies Analysts have maintained their price target for ArcticZymes Technologies at NOK 32.00, reflecting largely unchanged assumptions on fair value, revenue growth, and profit margins, while only slightly adjusting the discount rate and future price to earnings expectations. What's in the News ArcticZymes Technologies ASA has launched a share repurchase program starting November 25, 2025, allowing buybacks of up to 2,500,000 shares, or 4.90% of outstanding capital, with authorization valid until the 2026 AGM or June 30, 2026, whichever comes first (Key Developments).Anlatı Güncellemesi • Nov 25
AZT: Exclusive Distribution Partnership Will Drive European Expansion And Strengthen Margins
Analysts have adjusted their price target for ArcticZymes Technologies, keeping it at NOK 32.00. This decision is based on continued expectations for strong profit margins along with a more cautious perspective on future earnings multiples.Analiz Makalesi • Nov 20
More Unpleasant Surprises Could Be In Store For ArcticZymes Technologies ASA's (OB:AZT) Shares After Tumbling 28%
ArcticZymes Technologies ASA ( OB:AZT ) shareholders that were waiting for something to happen have been dealt a blow...Anlatı Güncellemesi • Nov 10
AZT: Exclusive Distribution Deal Will Improve Profitability And European Market Presence
Analysts have maintained their fair value estimate for ArcticZymes Technologies at NOK 32.00, citing stable profit margin improvements and changes in the revenue growth outlook as key factors in their latest assessment. What's in the News ArcticZymes Technologies ASA and Brenntag Specialties Pharma have signed an exclusive distribution agreement for SAN-HQ and M-SAN enzymes across Europe.Anlatı Güncellemesi • Oct 27
Precision Medicine Will Continue Advancing Through Biomanufacturing And Gene Therapies
Analysts have maintained their fair value price target for ArcticZymes Technologies at NOK 32.00. They cite stable revenue growth and profitability projections as the basis for leaving their outlook unchanged.Anlatı Güncellemesi • Oct 13
Biomanufacturing And Gene Therapies Will Expand Precision Medicine
Analysts have raised their price target for ArcticZymes Technologies from NOK 29 to NOK 32. They cite updated growth forecasts and stronger margin expectations as key factors in the upward revision.Anlatı Güncellemesi • Aug 15
Biomanufacturing Advances Will Unlock Global Market Access
The significant increase in consensus analyst price target for ArcticZymes Technologies is primarily driven by notably higher forecasts for revenue growth and a rising future P/E multiple, resulting in an upward revision from NOK17.50 to NOK24.50. What's in the News Launched M-SAN HQ GMP, a new GMP-grade nuclease tailored for viral vector manufacturing, enabling high activity in physiological salt conditions and improving DNA removal without harsh buffers.Analiz Makalesi • Aug 15
What ArcticZymes Technologies ASA's (OB:AZT) 50% Share Price Gain Is Not Telling You
ArcticZymes Technologies ASA ( OB:AZT ) shareholders have had their patience rewarded with a 50% share price jump in...Analiz Makalesi • Mar 11
ArcticZymes Technologies ASA's (OB:AZT) 33% Share Price Surge Not Quite Adding Up
The ArcticZymes Technologies ASA ( OB:AZT ) share price has done very well over the last month, posting an excellent...Analiz Makalesi • Feb 15
ArcticZymes Technologies ASA's (OB:AZT) Intrinsic Value Is Potentially 43% Above Its Share Price
Key Insights The projected fair value for ArcticZymes Technologies is kr27.08 based on 2 Stage Free Cash Flow to Equity...
Yeni Anlatı • Jan 20
Transition To Solution Provider Will Accelerate Market Penetration By Late 2025
ArcticZymes is shifting from raw materials to solutions, aiming for revenue growth through closer customer interactions and market penetration by late 2025.Analiz Makalesi • Nov 28
Take Care Before Jumping Onto ArcticZymes Technologies ASA (OB:AZT) Even Though It's 25% Cheaper
To the annoyance of some shareholders, ArcticZymes Technologies ASA ( OB:AZT ) shares are down a considerable 25% in...Analiz Makalesi • Nov 12
Analysts Are More Bearish On ArcticZymes Technologies ASA (OB:AZT) Than They Used To Be
Market forces rained on the parade of ArcticZymes Technologies ASA ( OB:AZT ) shareholders today, when the analysts...Analiz Makalesi • Nov 09
ArcticZymes Technologies ASA Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts
There's been a major selloff in ArcticZymes Technologies ASA ( OB:AZT ) shares in the week since it released its...Analiz Makalesi • Aug 31
The Price Is Right For ArcticZymes Technologies ASA (OB:AZT) Even After Diving 28%
ArcticZymes Technologies ASA ( OB:AZT ) shareholders that were waiting for something to happen have been dealt a blow...Analiz Makalesi • Aug 30
ArcticZymes Technologies' (OB:AZT) Solid Earnings May Rest On Weak Foundations
ArcticZymes Technologies ASA's ( OB:AZT ) healthy profit numbers didn't contain any surprises for investors. We think...Analiz Makalesi • Aug 25
ArcticZymes Technologies ASA Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
It's been a sad week for ArcticZymes Technologies ASA ( OB:AZT ), who've watched their investment drop 13% to kr21.00...Analiz Makalesi • May 12
Earnings Miss: ArcticZymes Technologies ASA Missed EPS By 17% And Analysts Are Revising Their Forecasts
Last week, you might have seen that ArcticZymes Technologies ASA ( OB:AZT ) released its quarterly result to the...Analiz Makalesi • Feb 08
ArcticZymes Technologies' (OB:AZT) Shareholders Have More To Worry About Than Only Soft Earnings
Last week's earnings announcement from ArcticZymes Technologies ASA ( OB:AZT ) was disappointing to investors, with a...Analiz Makalesi • Feb 04
ArcticZymes Technologies ASA Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
There's been a major selloff in ArcticZymes Technologies ASA ( OB:AZT ) shares in the week since it released its yearly...Analiz Makalesi • Feb 02
Investors Aren't Buying ArcticZymes Technologies ASA's (OB:AZT) Revenues
When close to half the companies operating in the Biotechs industry in Norway have price-to-sales ratios (or "P/S...Hissedar Getirileri
| AZT | NO Biotechs | NO Pazar | |
|---|---|---|---|
| 7D | 2.5% | -0.6% | -2.2% |
| 1Y | 23.0% | 28.3% | 11.6% |
Getiri vs. Endüstri: AZT geçen yıl % 28.3 oranında getiri sağlayan Norwegian Biotechs sektörünün gerisinde kaldı.
Getiri vs Piyasa: AZT geçen yıl % 11.6 oranında getiri sağlayan Norwegian Piyasasını aştı.
Fiyat Oynaklığı
| AZT volatility | |
|---|---|
| AZT Average Weekly Movement | 7.7% |
| Biotechs Industry Average Movement | 7.7% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in NO Market | 11.0% |
| 10% least volatile stocks in NO Market | 3.2% |
İstikrarlı Hisse Senedi Fiyatı: AZT hisse senedi fiyatı, son 3 ayda Norwegian piyasasına kıyasla dalgalı seyretti.
Zaman İçindeki Volatilite: AZT 'nin haftalık oynaklığı ( 8% ) geçen yıl boyunca sabit kaldı, ancak hala Norwegian hisselerinin %75'inden yüksek.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1990 | 51 | Michael Akoh | www.arcticzymes.com |
Bir yaşam bilimleri şirketi olan ArcticZymes Technologies ASA, Norveç, Almanya, Litvanya, Fransa, İtalya, Birleşik Krallık, Avrupa'nın geri kalanı, Amerika Birleşik Devletleri ve uluslararası alanda moleküler araştırma, in vitro teşhis ve biyo-üretimde kullanılmak üzere rekombinant enzimler geliştirmekte, üretmekte ve ticarileştirmektedir. Şirket, Sanger dizileme ve yeni nesil dizileme işlemlerinden önce temizleme için karides alkalin fosfataz; kontamine dU-DNA'nın uzaklaştırılması için viral ve diğer moleküler tanı testlerinde kullanılmak üzere morina UNG; viral vektörlerin, rekombinant proteinlerin ve diğer reaktiflerin üretimi sırasında nükleik asitlerin uzaklaştırılması için tuz aktif nükleazlar ve çift sarmallı DNA'nın uzaklaştırılması için çift sarmala özgü DNazlar ve türetilmiş kitler sunmaktadır. Ayrıca yaşam bilimleri, moleküler teşhis, NGS ve sentetik biyoloji için teknoloji geliştirmeye yönelik DNA/RNA polimerazlar; mikrobiyolojik teşhis ve sıvı biyopsiler için proteinazlar; ve nükleik asitleri birleştirmek için ligazlar sağlamaktadır.
ArcticZymes Technologies ASA Temel Bilgiler Özeti
| AZT temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | NOK 1.05b |
| Kazançlar(TTM) | NOK 13.43m |
| Gelir(TTM) | NOK 128.37m |
78.3x
F/K Oranı8.2x
P/S OranıAZT aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| AZT gelir tablosu (TTM) | |
|---|---|
| Gelir | NOK 128.37m |
| Gelir Maliyeti | NOK 6.14m |
| Brüt Kâr | NOK 122.23m |
| Diğer Giderler | NOK 108.80m |
| Kazançlar | NOK 13.43m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
Aug 14, 2026
| Hisse başına kazanç (EPS) | 0.26 |
| Brüt Marj | 95.22% |
| Net Kâr Marjı | 10.46% |
| Borç/Özkaynak Oranı | 0% |
AZT uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/06/16 00:03 |
| Gün Sonu Hisse Fiyatı | 2026/06/16 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
ArcticZymes Technologies ASA 6 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Mikkel Nyholt-Smedseng | Carnegie Investment Bank AB |
| Espen Jørgensen | DNB Carnegie |
| Viktor Sundberg | Nordea Markets |